MARAVAI LIFESCIENCES HOLDINGS, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
MRVI$7.86-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenue | $185,743 | $259,185 | $288,945 |
| Cost of revenue | 151,753 | 150,876 | 148,743 |
| Gross profit | 33,990 | 108,309 | 140,202 |
| Operating expenses: | |||
| Selling, general and administrative | 145,118 | 161,771 | 151,390 |
| Research and development | 17,402 | 19,221 | 17,280 |
| Change in estimated fair value of contingent consideration | 200 | (2,003) | (3,286) |
| Impairment of goodwill and long-lived assets | 68,709 | 166,151 | — |
| Restructuring | 17,827 | (1,214) | 6,466 |
| Total operating expenses | 249,256 | 343,926 | 171,850 |
| Loss from operations | (215,266) | (235,617) | (31,648) |
| Other income (expense): | |||
| Interest expense | (26,992) | (47,700) | (45,892) |
| Interest income | 11,436 | 27,403 | 27,727 |
| Loss on extinguishment of debt | — | (3,187) | — |
| Change in payable to related parties pursuant to the Tax Receivable Agreement | — | (40) | 668,886 |
| Other expense | (4,152) | (2,341) | (1,337) |
| (Loss) income before income taxes | (234,974) | (261,482) | 617,736 |
| Income tax (benefit) expense | (4,212) | (1,860) | 756,111 |
| Net loss | (230,762) | (259,622) | (138,375) |
| Net loss attributable to non-controlling interests | (99,989) | (114,776) | (19,346) |
| Net loss attributable to Maravai LifeSciences Holdings, Inc. | $(130,773) | $(144,846) | $(119,029) |
| Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted | $(0.90) | $(1.05) | $(0.90) |
| Weighted average number of Class A common shares outstanding, basic and diluted | 144,360 | 137,906 | 131,919 |
The accompanying notes are an integral part of these consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.